Advertisement
Screener

Trevi Therapeutics, Inc. (TRVI) ROA

Trevi Therapeutics, Inc. ROA

Return on assets (ROA) is the profit a company earns for every dollar of assets it uses, shown as a percentage. It is net income divided by total assets, and the table shows both amounts. Because assets are funded by lenders as well as shareholders, ROA is not inflated by borrowing the way ROE can be, and it is naturally lower for businesses that need many factories, stores or other assets. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • Trevi Therapeutics, Inc. roa for the quarter ending 2026-06-30 was -15.46%, a change of 7.24% year-over-year.
  • Trevi Therapeutics, Inc. roa for the quarter ending 2026-03-31 was -25.40%, a change of 18.85% year-over-year.
  • Trevi Therapeutics, Inc. roa for the quarter ending 2025-12-31 was -22.10%, a change of 21.10% year-over-year.
  • Trevi Therapeutics, Inc. roa for the quarter ending 2025-09-30 was -23.00%, a change of 41.31% year-over-year.
  • Trevi Therapeutics, Inc. roa for fiscal 2025 was -22.10%, a change of 21.10% from fiscal 2024.
  • Trevi Therapeutics, Inc. roa for fiscal 2024 was -43.20%, a change of -10.69% from fiscal 2023.
  • Trevi Therapeutics, Inc. roa for fiscal 2023 was -32.51%, a change of -8.81% from fiscal 2022.
  • Trevi Therapeutics, Inc. roa for fiscal 2022 was -23.70%, a change of 64.52% from fiscal 2021.
Available history
2018-12-31 to 2026-06-30
Data captured

Historical ROA

DateROANet income 12 monthNet income 3 monthTotal assets
2026-06-30-15.46%-$51.11M-$17.80M$330.52M
2026-03-31-25.40%-$45.61M-$13.19M$179.61M
2025-12-31-22.10%-$42.76M-$8.32M$193.44M
2025-09-30-23.00%-$45.86M-$11.80M$199.36M
2025-06-30-22.70%-$47.3M-$12.30M$208.34M
2025-03-31-44.25%-$47.35M-$10.34M$107M
2024-12-31-43.20%-$47.91M-$11.41M$110.9M
2024-09-30-64.31%-$44.32M-$13.24M$68.91M
2024-06-30-52.53%-$38.77M-$12.35M$73.81M
2024-03-31-42.73%-$33.57M-$10.90M$78.56M
2023-12-31-32.51%-$29.07M-$7.83M$89.4M
2023-09-30-27.89%-$26.75M-$7.70M$95.9M
2023-06-30-27.05%-$27.32M-$7.14M$100.98M
2023-03-31-24.29%-$28.22M-$6.40M$116.21M
2022-12-31-23.70%-$29.15M-$5.50M$123.02M
2022-09-30-25.06%-$32.17M-$8.27M$128.36M
2022-06-30-38.27%-$31.16M-$8.05M$81.41M
2022-03-31-108.27%-$32.9M-$7.33M$30.39M
2021-12-31-88.21%-$33.94M-$8.52M$38.48M
2021-09-30-110.59%-$34.94M-$7.25M$31.6M
2021-06-30-89.57%-$35.07M-$9.79M$39.15M
2021-03-31-76.19%-$32.66M-$8.37M$42.86M
2020-12-31-69.50%-$32.76M-$9.52M$47.13M
2020-09-30-53.28%-$29.77M-$7.38M$55.88M
2020-06-30-63.30%-$29.76M-$7.38M$47.01M
2020-03-31-54.80%-$29.72M-$8.47M$54.24M
2019-12-31-43.42%-$26.05M-$6.54M$60M
2019-09-30-38.62%-$25.5M-$7.37M$66.02M
2019-06-30-31.66%-$23.78M-$7.35M$75.12M
2019-03-31-123.92%-$21.3M-$4.80M$17.19M
2018-12-31-195.18%-$20.55M-$5.98M$10.53M

Annual ROA

DateROANet income 12 monthTotal assets
2025-12-31-22.10%-$42.76M$193.44M
2024-12-31-43.20%-$47.91M$110.9M
2023-12-31-32.51%-$29.07M$89.4M
2022-12-31-23.70%-$29.15M$123.02M
2021-12-31-88.21%-$33.94M$38.48M
2020-12-31-69.50%-$32.76M$47.13M
2019-12-31-43.42%-$26.05M$60M
2018-12-31-195.18%-$20.55M$10.53M

Similar stocks

Stock NameCountryMarket CapPE Ratio
PALVELLA THERAPEUTICS, INC. (PVLA)United States$2.105B-35.55
Braveheart Bio, Inc. (BRVE)United States$2.106B
Bausch Health Companies Inc. (BHC)$2.113B-1.68
Generate Biomedicines, Inc. (GENB)United States$2.052B
PERRIGO Co plc (PRGO)Ireland$2.038B-0.79
NEKTAR THERAPEUTICS (NKTR)United States$2.026B-9.05
OCULAR THERAPEUTIX, INC (OCUL)United States$2.159B-7.15
Prestige Consumer Healthcare Inc. (PBH)United States$2.163B13.03
UroGen Pharma Ltd. (URGN)$2.015B-18.42
Nuvation Bio Inc. (NUVB)United States$2.007B-13.12